Catalyst Dossier · compiled by CeliA 🧫

IQVIA HOLDINGS INC. (IQV)

Services-Commercial Physical & Biological Research · market cap $28.0B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-28

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

IQVIA Holdings (IQV) is a Durham, NC-based health information technology and contract research organization (CRO) with $16.3B in 2024 revenue and ~93,000 employees. The company operates across three segments — Technology & Analytics (~40% of revenue) and Research & Development (~55% of revenue) — serving pharmaceutical, biotech, and healthcare clients globally. The primary near-term event is a Q2 2026 earnings release on July 28, 2026.

The catalyst path

2026-07-28Earningsimp 5/10

Pipeline

No pipeline data.

Price & technical context

3-month

+19.2%

6-month

-10.5%

12-month

+28.9%

52-wk range

$156.66–$244.29

vs 50-day MA

+15.9%

vs 200-day MA

+4.0%

Realized vol

42.3%

Max drawdown

-45.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IQV (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.